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Background: Increased survival after cancer in young age has made long-term follow-up studies of high external validity
important. In this national cohort study, we explored the impact of cancer in young age on reproduction and marital status in male
survivors.
Methods: Hazard ratios (HRs) and relative risks (RRs) of reproductive and marital outcomes were studied for male survivors of
cancer in young age (o25 years) and cancer-free male comparisons, born during 1965–1985, by linking compulsory national
registries in Norway.
Results: Male cancer survivors (n¼ 2687) had reduced paternity (HR: 0.72, 95% confidence interval (CI): 0.68–0.76). This was most
apparent in survivors of testicular cancer, brain tumours, lymphoma, leukemia and bone tumours, and when diagnosed with
cancer before 15 years of age. Male cancer survivors were more likely to avail of assisted reproduction (RR: 3.32, 95% CI: 2.68–4.11).
There was no increased risk of perinatal death, congenital malformations, being small for gestational age, of low birth weight or
preterm birth in their first offspring. Male cancer survivors were less likely to marry (HR: 0.93, 95% CI: 0.86–1.00), in particular brain
tumour survivors.
Conclusions: In this national cohort study, we demonstrated reduced paternity and increased use of assisted reproduction among
male cancer survivors, but no adverse outcome for their first offspring at birth.
The number of survivors after treatment of cancer in childhood,
adolescence and young adulthood has steadily increased over the
past decades (Steliarova-Foucher et al, 2004), due to improvements
in treatment regimens and supportive care. It is now expected that
close to 80% of those diagnosed with cancer during childhood or
adolescence will survive their cancer and subsequent treatment
(Steliarova-Foucher et al, 2004; Gatta et al, 2014). This leads to a
growing number of adults in need of specialised care and
counselling during specific life events, such as attempts to establish
a family and reproductive health issues. In the United States, B1
out of 530 adults between the age of 20 and 39 years is currently a
survivor of paediatric cancer (Ward et al, 2014) and this number is
expected to rise as the survivors of the recent decades with
improved cancer treatment reach adult age.
However, as treatment for these cancers has become more
successful, the concern regarding severe late effects has also
increased. Adult survivors of childhood cancer have a high
prevalence of adverse health outcomes, especially pulmonary,
cardiac and endocrine (Hudson et al, 2013; de Fine Licht et al,
2014; Gudmundsdottir et al, 2015), as well as risk of secondary
malignancies (Oeffinger et al, 2006; Geenen et al, 2007; Olsen
et al, 2009).
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The effects of previous cancer treatment on pregnancy and
reproductive outcomes among female survivors diagnosed with
cancer in young age are relatively well explored (Green et al, 2009;
Reulen et al, 2009; Signorello et al, 2012). Less detailed and
comprehensive information is, however, available regarding male
survivors and studies are often hampered by a limited number of
participants, selection bias and low power (Green et al, 2010;
Tromp et al, 2011; Van Dorp et al, 2012; Wasilewski-Masker et al,
2014). The objective of this study was to examine detailed
reproductive outcomes of men diagnosed with cancer before the
age of 25 years in a complete, national cohort. By linking several
compulsory national databases in Norway holding medical, social
and demographic data, we assessed medical aspects of reproduc-
tion at a population level (paternity, the use of assisted
reproductive technology (ART) and offspring outcomes) and also
whether a potential difference in paternity rates could be explained
by a difference in the ability to find a partner (social aspect of
reproduction). Our registry design rewarded us a large population-
based cohort of high scientific validity available for analysis.
MATERIALS AND METHODS
Data sources. The Cancer Registry of Norway (CRN) has received
information on all patients with a cancer diagnosis since 1953.
Reporting is mandatory for all clinicians and pathologists in
Norway (Cancer Registry of Norway, 2013), and information about
site, histological type and stage of disease at the time of diagnosis is
recorded. The completeness of the CRN has been found to be
495% (Larsen et al, 2009), consistent with other Northern
European cancer registries (Gatta et al, 2014). Cancer Registry of
Norway provided information on the cancer cases including date
of diagnosis, site (International Classification of Disease, Seventh
Edition (ICD-7; World Health Organization, 1957) and, for some
diagnoses (leukemia, lymphoma and central nervous system (CNS)
tumours), tumour morphology (Manual of Tumor Nomenclature
and Coding (MOTNAC; American Cancer Society, 1968) for
cancers diagnosed until 1992 and International Classification of
Diseases for Oncology, Second Edition (ICD-O-2) morphology
codes from 1993 onwards (World Health Organization, 1990;
Larsen et al, 2009)).
The Medical Birth Registry of Norway (MBRN) holds informa-
tion on all births in Norway since 1967 (Irgens, 2000; Medical
Birth Registry of Norway, 2013). The Medical Birth Registry of
Norway is based on compulsory notification of every birth or late
abortion from 16 weeks of gestation onwards and includes
identification of the parents, complications during pregnancy and
delivery, length of pregnancy, as well as information on the infant.
The registry contains information on the use of ART from 1984
and close to complete data on the uptake of ART services in
Norway, including method of treatment (in-vitro fertilisation,
intracytoplasmic sperm injection (ICSI), combination or non-
specified), is available from 1988 onwards (Romundstad et al,
2008). We identified members of the study cohort registered in
MBRN as fathers. For their first offspring, MBRN provided
information on stillbirths and neonatal deaths, gestational age,
birth weight, congenital anomalies and whether the birth was a
result of ART (including method).
The Central Population Registry contains demographic
information on all residents in Norway from 1960 onwards
(Norwegian Tax Administration, 2015). The registry provided
date of birth, emigration or death and information on marital
status. Data on education were provided by the Norwegian
National Education Database, where all education statistics on an
individual level has been registered since 1970 (National Education
Database, 2013).
Every resident in Norway has since 1960 been assigned a unique
11-digit personal identification number, which enables precise
record linkage between registries.
Study cohort. Our study cohort consisted of all males born alive
in Norway during the 20-year period from 1965 through 1985.
Those who lacked an identification number, emigrated or died
before the start of reproductive age (defined here as 15 years)
were excluded (n¼ 16 140). The cancer cases were identified
through the CRN and information was available for cancers
diagnosed through 31 December 2007. We excluded those who
had an uncertain basis for their cancer diagnosis or a cancer
diagnosis at autopsy only (n¼ 217). The cancer site grouping
used for this study was based on a modified version of the
International Classification of Childhood Cancer, Second
Edition (Kramarova and Stiller, 1996), based on ICD-O-2 and
MOTNAC morphology codes, as well as ICD-7 topography
codes. For the tumours of the CNS, we divided the cancer
diagnoses into low- and high-grade tumours according to the
WHO classification (Louis et al, 2007). The term cancer survivor
was used to encompass all individuals diagnosed with cancer
before age 25 years and surviving beyond reproductive age (15
years of age).
The male cancer survivors who were diagnosed with a second
cancer (n¼ 82) during follow-up were excluded from the analyses.
There were missing data on marital status for 4539 individuals
including 143 of the cancer survivors.
Statistical analyses. We estimated the hazard ratio (HR) with a
95% confidence interval (CI) of fathering a first offspring in the
male cancer survivors compared with the non-cancer male group,
using Cox regression. We started follow-up at 15 years of age,
ended at the date of birth of the first offspring and censored at
death, emigration or 31 December 2011, whichever occurred
first. We then categorised the cancer cohort into diagnostic
groups (as described), age at diagnosis (0–14 years, 15–19 years
and 20–24 years) and diagnostic time periods (1965–79, 1980–94
and 1995–2007), and repeated the analyses on these subgroups.
In order to fully make use of the prospective nature of our
data and account for changes in the hazard rates over time, we
formed a time-dependent Cox regression model. For this model
studying paternity (defined as the date of birth of the first
offspring) as outcome, we defined age at cancer diagnosis as a
time-dependent covariate. This covariate was equal to 0 as long
as the cohort member had not been diagnosed with cancer
before the age of 25 years and changed value to 1 when cancer
(o25 years of age) was diagnosed. For the cohort member
diagnosed with cancer before 15 years of age, this covariate was
equal to 1 at the start of the follow-up. By using this model, the
cancer survivors fathering their first child before their cancer
was diagnosed (n¼ 72) were included in the non-cancer
comparison group for this analysis. We decided to study the
first offspring only, as this is the most unambiguous measure of
parenthood in the absence of both treatment data and data on
reproductive desire.
Adjustments were made by including year of birth of the cohort
members as a continuous variable, as well as parental education
(highest educational level achieved by the parents of the cohort) as
a categorical variable, divided into three categories: lower
education (o11 years), intermediate (11–14 years) and tertiary
education (414 years).
For the analysis on marriage, this was similarly modelled as
described above, with an extended Cox model including age at
cancer diagnosis as a time-dependent covariate. The follow-up
ended at the date of first marriage and cases were censored at
death, emigration or 31 December 2007, whichever occurred first.
Thus, the male cancer survivors who married before receiving their
cancer diagnosis were included in the non-cancer reference group
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for the analysis on marriage. This was done to make correct use of
the prospective nature of the data and to avoid conditioning on a
future cancer diagnosis. We then analysed paternity in the married
men only, for the cancer survivors compared with the cancer-free
male reference group. In this analysis, we started follow-up of the
childless males at the age of 15 years and ended at the date of birth
of the cohort member’s first offspring, censoring at death,
emigration or 31 December 2011, whichever occurred first. Here,
a standard Cox proportional hazard regression model was
employed and only the married men (n¼ 204 652) were part of
this sub-analysis. In addition to adjustments described for the
previous analyses, this analysis was also adjusted for the cohort
member’s age at marriage.
We estimated the relative risk (RR) of perinatal death
(comprising stillbirth 422 weeks gestation and neonatal death
o28 days), congenital anomalies, preterm birth (subdivided into
gestational age of 22–28 weeks and 29–36 weeks), low birth weight
(subdivided into birth weight of 500–1499 g and 1500–2499 g),
small for gestational age (SGA) and the risk of the pregnancy being
conceived using assisted reproduction, in the male cancer survivors
first offspring compared with the first offspring of the cancer-free
reference group. A log binomial regression model was employed
and the results are presented as RRs with 95% CIs. For the analysis
on prematurity, low birth weight and SGA, we included only
singleton pregnancies. Small for gestational age was defined as
birthweight below  2 s.d. from the mean, sex-specific for each
gestational age in weeks (Skjærven et al, 2000). Adjustments were
made for birth year of the offspring’s father (the cohort member)
and age of the offspring’s mother (the partner of the cohort
member).
SPSS version 21 (IBM SPSS, Armonk, NY, USA) and STATA
version 12 (StataCorp LP, College Station, TX, USA) were used for
statistical analyses. Figure 1 was made in R statistical software
version 3.2.2 (R Foundation for Statistical Computing, Vienna,
Austria). The study was approved by the Norwegian Data
Protection Authority and the Regional Committee for Medical
and Health Research Ethics for Western Norway.
RESULTS
A total of 626495 males were born in Norway from 1965 through 1985.
After excluding those who emigrated or died before fertile age, the
study cohort comprised 2687 cancer survivors diagnosed with cancer
before the age of 25 years and 607668 cancer-free male comparisons
(Table 1). There were 1087 first offspring among the male cancer
survivors, the corresponding number being 368469 in the male non-
cancer reference group. Thirty per cent of the cancer cases were
diagnosed in childhood (0–14 years of age), 26% in adolescence (15–19
years) and 43% in young adulthood (20–24 years). There were relatively
few survivors being diagnosed in the first time period of 1965–1979
(9%) and thus the majority was diagnosed after 1980 (Table 1).
The most prevalent cancer type overall was gonadal and germ
cell tumours (27% of which the majority were diagnosed as young
adults), hereafter referred to as ‘testicular cancer’, followed by CNS
tumours (18%), lymphoma (15%) and leukemia (13%; Table 1).
We observed a significant reduction in paternity in the male
cancer survivors (HR: 0.72, 95% CI: 0.68–0.76) compared with the
non-cancer males (Figure 1A). Divided into cancer site, we found
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Figure 1. Forest plot of hazard ratios for paternity and marriage. (A) Hazard ratios (HRs) with 95% CIs of fathering a first offspring after cancer
diagnosis, for all cancer survivors (n¼ 2605, secondary malignancies excluded), subdivided into different cancer diagnoses, with the non-cancer
male population as reference (n¼607668). (B) Hazard ratios with 95% CIs of marriage in the cancer survivors (n¼ 2462), with the cancer-free male
population as reference (n¼ 603272). (C) Hazard ratios with 95% CIs of fathering a first offspring in the married population only, in the cancer
survivors (n¼667) versus the male non-cancer reference population (n¼ 203985). The horizontal lines through the squares represent 95% CI,
arrows indicate upper CI above 2.5. Solid boxes indicate HR in each cancer group with dimensions proportional to weights (inverse of s.d.). The
diamonds represent the pooled HR for all cancers, with 95% CI. All analyses are adjusted for birth year of the cohort members (father) and
education of parents; and for the analysis presented in C, adjustment was also made for age (of cohort member) at marriage. Age at cancer
diagnosis was entered as a time-varying covariate in the extended Cox regression analysis for A and B. Only results from cancer groups containing
430 survivors are depicted. The cancer site grouping used is a modified version of the International Classification of Childhood Cancer
(Kramarova and Stiller, 1996), based on ICD-O-2 and MOTNAC morphology codes and ICD-7 topography codes. The grading of CNS tumours is
based on the 2007 WHO classification of tumours of the CNS (Louis et al, 2007).
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significantly reduced paternity in survivors of testicular cancer,
CNS tumours (both low grade, high grade and unspecified),
lymphoma (both Hodgkin lymphoma (HL) and non-HL),
leukemia, malignant bone and sympathetic nervous system
tumours, as well as retinoblastoma.
When studying the impact of time period of cancer diagnosis
and age at cancer diagnosis, we found the reduction in paternity in
our material most pronounced in the patients receiving a cancer
diagnosis before 1995 (HR: 0.61, 95% CI: 0.51–0.72 (diagnosed
1965–79); HR: 0.66, 95% CI: 0.61–0.72 (1980–94)) and among
those diagnosed below age 15 years (HR: 0.59, 95% CI: 0.52–0.66).
Adjustment for parental education and birth year did not change
our estimates.
The first offspring of the male cancer survivors did not have an
increased risk of perinatal death or congenital anomalies (Table 2),
neither when analysing only major birth defects (according to the
EUROCAT classification (EUROCAT, 2012)), nor when the
subgroups of cancer diagnoses were analysed separately (results
not shown). There were a total of 42 first offspring of the male
cancer survivors registered with a congenital malformation in the
MBRN (4%). Similarly, we could not demonstrate any increased
risk for preterm birth (22–36 completed weeks of gestation), low
birth weight (500–2499 g) or being SGA, in the offspring of male
cancer survivors (Table 2). All estimates for adverse offspring
outcomes of the male cancer survivors in comparison with the
non-cancer male reference group were below 0, suggesting no
increased risk for adverse outcomes, although not reaching
statistical significance. Although including multiple pregnancies
for analysis provided similar results, the results presented include
singleton births only.
There was a threefold increased likelihood of pregnancies
resulting from ART (RR: 3.32, 95% CI: 2.69–4.10) for the male
cancer survivors’ first offspring (Table 3). For sub-analyses on the
associations between assisted reproduction and age at cancer
diagnosis as well as treatment period, this was only significant for
fathers diagnosed with cancer after 14 years of age and after 1980
(results not shown), although based on small numbers. The use of
ART to impregnate their partner was significantly increased for
survivors of testicular cancer, CNS tumours, lymphoma, leukemia,
malignant bone tumours, sympathetic nervous system tumours
and thyroid cancer, although there were small numbers in the three
latter cancer groups (Table 3). With regards to method of ART,
Table 1. Characteristics of the male cancer survivors
Age at diagnosis Calendar year of diagnosis
Number (% of total number in age
category)
Number (% of total number in
diagnostic period)
Diagnostic groupa 0–14 Years 15–19 Years 20–24 Years 1965–79 1980–94 1995–07 Total (%)
I. Leukemia 214 (26.1) 74 (10.4) 54 (4.7) 59 (23.9) 207 (15.4) 76 (6.9) 342 (12.7)
Lymphoblastic leukemia 169 51 19 45 149 45 239
Myeloid leukemia 18 16 23 3 33 21 57
Leukemia, unspecified 27 7 12 11 25 10 46
II. Lymphoma 97 (11.8) 131 (4.5) 182 (15.7) 20 (8.1) 211 (15.7) 179 (16.4) 410 (15.3)
Hodgkin lymphoma 41 76 127 7 116 121 244
Non-Hodgkin lymphomab 50 55 53 8 93 57 158
Lymphoma,unspecified 6 0 2 5 2 1 8
III. CNS neoplasmsc 214 (26.1) 122 (17.1) 150 (13.0) 60 (24.3) 260 (19.3) 166 (15.2) 486 (18.1)
Low grade 148 76 96 44 170 106 320
High grade 34 25 27 8 54 24 86
Unspecified 32 21 27 8 36 36 80
IV. Sympathetic nervous system tumours 40 (4.9) 4 (0.6) 5 (0.4) 19 (7.6) 27 (2.0) 3 (0.3) 49 (1.8)
V.Retinoblastoma 39 (4.8) 0 (0) 0 (0) 17 (6.9) 22 (1.6) 0 (0) 39 (1.5)
VI. Renal tumours 56 (6.8) 1 (0.1) 4 (0.3) 30 (12.1) 27 (2.0) 4 (0.4) 61 (2.3)
VII. Hepatic tumours 8 (1.0) 3 (0.4) 3 (0.3) 5 (2.0) 8 (0.6) 1 (0.1) 14 (0.5)
VIII. Malignant bone tumours 38 (4.6) 61 (8.6) 29 (2.5) 7 (2.8) 77 (5.7) 44 (4.0) 128 (4.8)
IX. Soft tissue sarcomas 28 (3.4) 30 (4.2) 15 (1.3) 4 (1.6) 50 (3.7) 19 (1.7) 73 (2.7)
X. Germ cell and other gonadal neoplasms 39 (4.8) 179 (25.1) 516 (44.6) 16 (6.4) 284 (21.1) 434 (39.7) 734 (27.3)
XI. Carcinomas and other malignant epithelial neoplasms
Thyroid carcinomad 5 (0.6) 11 (1.5) 21 (1.8) 0 (0) 21 (1.6) 16 (1.5) 37 (1.4)
Malignant melanoma 13 (1.6) 40 (5.6) 77 (6.7) 3 (1.2) 69 (5.1) 58 (5.3) 130 (4.8)
Skin, non-melanomae 9 (1.1) 10 (1.4) 24 (2.1) 2 (0.8) 18 (1.3) 23 (2.1) 43 (1.6)
Colon 0 (0) 6 (0.8) 19 (1.6) 0 (0) 6 (0.4) 19 (1.7) 25 (0.9)
Urinary/bladder 4 (0.5) 5 (0.7) 9 (0.8) 2 (0.8) 9 (0.7) 7 (0.6) 18 (0.7)
XII. Other and unspecified malignant neoplasms 15 (1.8) 35 (4.9) 48 (4.2) 3 (1.2) 50 (3.7) 45 (4.1) 98 (3.6)
Total 819 (100) 712 (100) 1156 (100) 247 (100) 1346 (100) 1094 (100) 2687f (100)
Abbreviations: CNS¼ central nervous system; ICD-7¼ International Classification of Disease, seventh edition; ICD-O-2¼ International Classification of diseases for oncology, second edition;
MOTNAC¼Manual of Tumor Nomenclature and Coding. Characteristics of the male cancer survivors (including overall and specific cancer sites), stratified according to age and time period of
cancer diagnosis.
aThe cancer site grouping used is a modified version of the International Classification of Childhood Cancer (Kramarova and Stiller, 1996), based on ICD-O-2 and MOTNAC morphology codes
and ICD-7 topography codes.
bIncluding Burkitt lymphoma.
cThe grading of CNS tumours is based on the 2007 WHO classification of tumours of the CNS (Louis et al, 2007).
dIncluding adrenal (endocrine) carcinoma (n¼ 3).
eExcluding basal cell carcinoma, site grouping based on ICD-7 site code 190.
fIncluding 82 individuals with a secondary malignancy.
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there was a significantly increased usage of ICSI compared with
in vitro fertilisation and unspecified methods in the partners of
male cancer survivors compared with the partners of the male
non-cancer reference group (RR: 1.51, 95% CI: 1.25–1.81;
Supplementary Table). Male cancer survivors had a slightly lower
likelihood of getting married compared with the non-cancer group
(HR: 0.93, 95% CI: 0.86–1.00; Figure 1B). In the CNS tumour
group, there was a significantly decreased likelihood of marriage in
the low-grade and nonspecific tumour groups, but in the high-
grade group this reduction was not significant. For survivors of
testicular cancer, lymphoma and leukemia, we found similar
marriage rates to the non-cancer male group (Figure 1B). When
analysing the married sub-cohort only, the paternity deficit for the
male cancer survivors remained (HR: 0.71, 95% CI: 0.66–0.78;
Figure 1C), and especially in the subgroups of testicular cancer,
lymphoma and leukemia. The reduced paternity in the CNS
tumour group, however, was less pronounced when restricting
analyses to the married individuals only.
DISCUSSION
In this national cohort study of Norwegian males born over a 20-
year period, we found significantly reduced paternity in men
diagnosed with cancer before the age of 25 years when compared
with the non-cancer reference group, especially when diagnosed
with cancer before age 15 years. Pregnancies conceived by ART
were significantly increased, but we could not demonstrate any
increased risk for adverse outcomes among the first offspring of the
survivors. Male cancer survivors had a slightly lower probability to
marry and the paternity deficit persisted when analysing the
married individuals only, except for the CNS tumour group.
One strength of the study is the use of compulsory national
registries not prone to selection bias and with minimal loss to
follow-up. Thus, our sample size is large and fully complete on a
population level. Furthermore, health care in Norway is free of
charge and provided independent of geographical location and
patient age (Molven and Ferkis, 2011).
A weakness of the study is the lack of detailed information on
individual cancer treatment. However, treatment for childhood
cancer in Norway has for the past 30 years been standardised by
common Nordic or European treatment protocols, and given at a
small number of centres, ensuring identical treatment regimens
for all children with cancer (Gustafsson et al, 2000; Pritchard-Jones
et al, 2013) and making assumptions as to which treatments
have been given in this group possible (Gustafsson et al, 1998; Moe
et al, 1997).
The great majority of male cancer survivors in our study were
diagnosed after 1980 (490%, Table 1) and for some cancer sites
there have been major changes in treatment regimens with regards
to gonadotoxicity since then. For testicular cancer, with the
introduction of retroperitoneal lymph node dissection and
cisplatin-based chemotherapy from 1980 onwards, this is regarded
as a major paradigm shift in the treatment (Fosså and Kravdal,
2000). For CNS tumours, there has been no major change in
treatment given over the past decades (Stensheim et al, 2011). For
HL in paediatric and adolescent patients, there has been an
ongoing process of reducing (and in selected cases omitting)
radiation since 1995 (Do¨rffel et al, 2013) as well as a shift towards
less gonadotoxic chemotherapy regimens (GPOH, 2015). For
(young) adult HL patients this has been a slower but nonetheless
ongoing process (Kiserud et al, 2007). In the case of non-HL, there
are no major changes in treatment strategies since 1980 (Stensheim
et al, 2011). For paediatric leukemia, omitting cranial irradiation
and replacing it with intermediate- and high-dose methotrexate
intravenously and intrathecally, has been the standard therapy in
Norway since 1975 (Moe et al, 1981). The agents in use for the
treatment of paediatric leukemia have not been subject to major
changes over the past few decades, although treatment combina-
tions and dosages have changed. There has been a significant
reduction in the use of irradiation for most paediatric cancers over
the past four decades (Jairam et al, 2013).
Our information regarding ART does not take into account
those who have attempted ART not leading to a successful
pregnancy. Our ART rates therefore serve as a surrogate marker
for ART attempts. There is no evidence to support that cancer
survivors would have a higher success rate from ART than cancer-
free individuals, thereby leading to an overestimation of the uptake
(Garcı´a et al, 2014). There is no information in the MBRN on the
use of sperm donors, which would have been useful for our study.
ART has been associated with adverse pregnancy outcomes
(Romundstad et al, 2008); however, despite an increased use of
Table 2. RR with 95% CI for selected first offspring outcomes
Offspring outcome
Male cancer survivorsa
(% of total first offspring)
Non-cancer male reference population
(% of total first offspring) RRb 95% CI
Perinatal deathc 6 (0.6) 2424 (0.7) 0.72 0.33–1.61
Congenital malformationd 42 (3.9) 15 395 (4.2) 0.92 0.69–1.24
Premature deliverye 52 (4.9) 21 490 (5.9) 0.83 0.63–1.08
22–28 Weeks 1 (0.1) 1625 (0.4) 0.21 0.03–1.50
29–36 Weeks 51 (4.8) 19 955 (5.5) 0.87 0.67–1.14
Low birth weighte 30 (3.0) 15 865 (4.4) 0.69 0.49–0.97
500–1499g 5 (0.5) 2927 (0.8) 0.59 0.25–1.41
1500–2499g 25 (2.4) 12 165 (3.4) 0.70 0.48–1.04
SGAe,f 17 (1.6) 7.979 (2.2) 0.75 0.46–1.19
Abbreviations: CI¼ confidence interval; RR¼ relative risk; SGA¼ small for gestational age. RR with 95% CI for selected first offspring outcomes in 1087 first singleton offspring of 2687 male
cancer survivors compared with 368 469 first singleton offspring of 607 668 individuals in the non-cancer male comparisons.
aCancer survivors with secondary malignancies (N¼ 82) are excluded from the analysis.
bAll analyses are adjusted for birth year of cohort members (fathers), mothers’ age and education of parents of cohort.
cPerinatal death¼ stillbirths 422 weeks gestational age and deaths o28 days of age. Of the six deceased offspring of cancer survivors, five were stillbirths and one was neonatal death (o28
days of age).
dThe congenital malformations in the cancer survivors’ offspring included hip deformity/dislocation (seven), foot deformities (four), patent ductus arteriosus (four), ventricular septal defects
(four), atrial septal defects (three), obstructive nephropathy (three), malformations of the gastrointestinal tract (two), cleft lip/palate, pulmonary stenosis, diaphragmatic hernia, hypoplasia of the
lung, agenesis of corpus callosum, neural tube defect, malformations in the skin and eye (all one). Some offspring were registered with more than one congenital malformation.
eMultiple pregnancies (N¼ 6245) are excluded from the analysis on prematurity, low birth weight and SGA.
fSGA is defined according to Skjærven et al (2000).
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ART among the male cancer survivors in our study, we could not
demonstrate an increased risk of negative outcomes among their
offspring. This applied also when studying the offspring of ART
only, in a separate analysis, although the numbers were too small to
firmly conclude (Supplementary Table). Several published studies
have explored the relationship between a cancer diagnosis and the
probability of having children (Madanat et al, 2008; Magelssen
et al, 2008; Green et al, 2010; Hudson, 2010). Most, although not
all, show reduced reproduction after surviving a cancer diagnosis,
in childhood, adolescence and in young adult age (Syse et al, 2007),
also depending on the site and stage of the cancer. There is, to our
knowledge, no population-based study to date looking at the
interplay of paternity, assisted reproduction, marriage and off-
spring outcomes in a national cohort of male survivors of cancer
diagnosed in childhood, adolescence and young adulthood. The
current study therefore adds important information regarding
these complex and interconnected issues, by studying them in a
population perspective.
We did not have complete information in our registries on
cohabitation rates and therefore used marriage as a marker for the
ability to sustain long-term relationships and establishing a family
unit. There is no evidence to support that childless cancer survivors
would marry more or less frequently (compared with cohabitating
without marrying) than the childless non-cancer males (Syse,
2008), nor did we find that the age at first marriage differed (data
not shown). In order to take into account socioeconomic status as a
possible factor influencing marriage and paternity, we adjusted all
analyses for educational achievement (highest education achieved)
of the parents of the cohort (as many of the cohort members might
not have completed their education at the time of analysis), which
did not change our estimates.
Studies have looked at cohabitation/marriage rates in cancer
survivors compared with siblings or with the cancer-free general
population, with somewhat conflicting results (Frobisher et al,
2007; Gurney et al, 2009; Koch et al, 2011; Kirchhoff et al, 2012;
Wengenroth et al, 2013). Syse (2008) did not find reduced
marriage rates in male survivors of any types of cancer (before age
44 years) in Norway, compared with the male population as a
whole, and only a nonsignificant slightly lower probability for
brain tumour survivors to marry, as well as an increased marriage
rate for survivors of testicular cancer. This is, despite a partial
overlap in study populations, contrary to our findings and
probably reflects the crucial timing of the treatment insult for
young male brain cancer patients in our study, as well as the fact
that childhood cancer survivors only contribute marginally to the
overall estimates for male survivors in the publication by Syse. A
Danish registry-based study (Koch et al, 2011) found a reduced
rate of cohabitation for childhood cancer survivors in general and
the largest deficit was found for survivors of CNS tumours, which
correspond well with our results.
We did not find an increased risk for detrimental effects of a history
of cancer in male survivors on pre- and perinatal outcomes of their
firstborn offspring. This has also been demonstrated in two previous
Norwegian studies (Magelssen et al, 2008; Stensheim et al, 2013),
Table 3. RR with 95% CI for pregnancies resulting from ART
Diagnostic groupsa
Offspring from ART
(total offspring) RRb 95% CI
No cancer 8278 (368 469) 1.00 (Ref)
All cancerc 80 (1087) 3.32 2.69–4.10
I. Leukemia 6 (121) 2.29 1.05–5.00
Lymphoblastic leukemia 3 (95) 1.463 0.48–4.44
Myeloid leukemia 1 (12) 3.76 0.57–24.84
Leukemia, unspecified 2 (14) 6.45 1.81–22.94
II. Lymphoma 15 (178) 3.79 2.34–6.15
Hodgkin lymphoma 12 (121) 4.45 2.60–7.60
Non-Hodgkin lymphomad 3 (50) 2.70 0.90–8.67
Lymphoma, unspecified 0 (7) * *
III. CNS neoplasmse 7 (132) 2.41 1.17–4.95
Low grade 6 (91) 2.94 1.36–6.38
High grade 0 (15) * *
Unspecified 1 (26) 1.84 0.27–12.541
IV. Sympathetic nervous system tumours 2 (15) 5.71 1.58–20.65
V. Retinoblastoma 0 (13) * *
VI. Renal tumours 2 (32) 2.20 0.55–8.79
VIII. Malignant bone tumours 4 (37) 4.77 1.89–12.06
IX. Soft tissue sarcomas 1 (34) 1.32 0.19–9.14
X. Germ cell and other gonadal neoplasms 38 (349) 3.70 2.69–5.09
XI. Carcinomas and other malignant epithelial neoplasms
Thyroid carcinomaf 2 (20) 4.36 1.17–16.31
Malignant melanoma 1 (80) 0.45 0.06–3.21
Abbreviations: ART¼ assisted reproductive technology; CNS¼ central nervous system; ICD-7¼ International Classification of Disease, seventh edition; ICD-O-2¼ International Classification of
diseases for oncology, second edition; MOTNAC¼Manual of Tumor Nomenclature and Coding. Relative risk (RR) with 95% Confidence interval (CI) for pregnancies resulting from ART in 80
partners of male cancer survivors (first offspring) when compared to 8,278 partners of the cancer-free male comparisons.
aThe cancer diagnostic groups defined are based on a modified version of the International Classification of Childhood Cancer (Kramarova and Stiller, 1996), based on ICD-O-2 and MOTNAC
morphology codes and ICD-7 topography codes. Only results for cancer groups with 430 cases are presented.
bAll analyses are adjusted for birth year of the cohort members (fathers) and age of the mother of the offspring. Owing to small numbers in some of our cancer diagnostic groups, the analysis is
run only in diagnostic groups containing 435 survivors.
cCohort members with secondary malignancies (N¼ 82) are excluded.
dIncluding Burkitt’s lymphoma.
eThe grading of CNS tumours is based on the 2007 WHO classification of tumours of the CNS (Louis et al, 2007).
fIncluding adrenal (extracranial endocrine gland) carcinoma.
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which have partly overlapping data with ours, although only
studying cancer diagnosed at 15 and 16 years and above,
respectively. However, there have been conflicting results pub-
lished with regards to the risk of congenital malformations in the
offspring of male cancer patients (Magelssen et al, 2008; Winther
et al, 2009; Ståhl et al, 2011; Signorello et al, 2012; Stensheim et al,
2013). A Norwegian (Magelssen et al, 2008) and a Swedish (Ståhl
et al, 2011) study found an increased risk of congenital
abnormalities in the offspring of male cancer survivors. However,
in the Norwegian study the data were from one hospital only,
cancers were diagnosed at age 15–35 years and the numbers
studied were relatively small. In the latter study, cancer was
diagnosed at all ages and there was no treatment data available.
The publications that were able to explore directly the link between
treatment exposure (especially radiation therapy to the gonads and
alkylating chemotherapy) and genetic disease in the offspring
(Signorello et al, 2012; Winther et al, 2012) could not provide
evidence for a causal relationship, which is in concordance with
our results (although we were not able to study treatment
exposures directly).
We briefly studied the impact of the diagnostic time period and
age at cancer diagnosis. As there are various co-dependent time
factors associated with a prospective study of a cancer cohort such
as ours, this could not be thoroughly studied within our design.
Some studies on adult survivors of cancer in young age have
described a reduction in late effects in survivors being treated with
more modern, and presumably less intense, treatment regimens
(Cvancarova et al, 2009; Stensheim et al, 2011), which is in
concordance with our results. Conflicting evidence exist with
regard to whether the prepubertal testis is protected from cytotoxic
insults or not (Rivkees, 1988; Green et al, 2014), although the most
recent publication cannot find any protective effect of being treated
pre-pubertally with alkylating agent chemotherapy on subsequent
adult sperm concentration. Our results suggest vulnerability in
children younger than 15 years at diagnosis. This may be
attributable to the fact that childhood cancers more often require
intensive, multi-modal therapy when compared with young adult
cancer, more so than a biological inherent vulnerability to the
toxicity of cancer treatment in pre-pubertal children. As we have
no access to treatment exposures in our study, we are not able to
explore this in detail. Owing to the selection of our cohort, the
male cancer survivors in the oldest age group at diagnosis will have
been treated with more modern treatment regimens and also at a
time when fertility preservation was becoming more available in
Norway (Stensvold et al, 2011).
As we use the national registry data, our data overlap in part
with earlier Norwegian studies published (Syse et al, 2007;
Magelssen et al, 2008; Syse, 2008; Stensheim et al, 2011, 2013).
Our findings, when comparable, line up well with existing, overall
conclusions and do not provide evidence that male childhood
cancer survivors (not included in all previous publications) in
general fare worse than survivors diagnosed with cancer at an older
age. This is an important information for the growing population
of childhood cancer survivors. Unfortunately, it is not possible to
disentangle the possible influences of data overlap versus non-
overlap and actual changes that have taken place in more recent
times, based on the published information. By jointly considering
birth outcomes, parenthood and marriage in a recent time period
in a complete national cohort, we contribute novel, updated
information on important aspects of adult living for Norwegian
male survivors of cancer diagnosed before 25 years of age. This
might be transferable to male cancer survivors not only in the
Nordic countries but also in non-Nordic countries, which share
some of the Nordic welfare traits, and hopefully will contribute to
developing adequate counselling and follow-up strategies for male
survivors of cancer in young age, during their transition into and
passage through adulthood.
Although a large proportion of male survivors of cancer in
young age will be able to establish a family and father children,
there is still room for improvement, especially with regards to
decreasing the toxicity burden of current treatment regimens, as
well as improving fertility preservation methods and access to these
for young male cancer patients.
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